Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Their lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Their proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific…More Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Their TME Normalization™ Technology allows their drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. They have uncovered fundamental biological systems that link oncology and inflammation. Their pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.